ESMO 35

 
 
 

The 35th ESMO Congress was held in Milan in October 2010. See below for HematologyTimes coverage.

 

VMPT plus VT maintenance improves PFS in MM

Alice Goodman Read Article
Published: 11/05/10

Multiple myeloma cells
Multiple myeloma cells

Initial therapy with a 4-drug cocktail, VMPT,  followed by maintenance therapy with 2 of those drugs (VT) significantly improved response rates and progression-free survival (PFS) compared with VMP, considered the best standard of care in patients with newly diagnosed multiple myeloma. The randomized phase 3 trial was conducted by the Italian Multiple Myeloma Network (GIMEMA) and was presented at the 35th Congress of the European Society of Medical Oncology (ESMO). [Read Article]

Following guidelines improves NHL survival

Alice Goodman Read Article
Published: 11/04/10

T-cell lymphoma cells
Bone marrow aspirate
showing T-cell lymphoma cells

Adherence to guideline-based indicators for diagnosis and treatment is associated with improved survival for patients with non-Hodgkin lymphoma (NHL), according to an observational, population-based study presented at a poster session during the 35th Congress of the European Society of Medical Oncology (ESMO). The study was conducted to determine if the quality of care as recommended by guidelines is related to 5-year overall survival for patients with NHL. [Read Article]

Three-drug consolidation in MM

Alice Goodman Read Article
Published: 10/26/10

Multiple myeloma cells
Multiple myeloma cells

A strategy of molecular targeting can achieve similar outcomes to that of high-dose chemotherapy and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, according to results of the first phase 3 study to compare high-dose chemotherapy plus stem cell transplantation against conventional-dose chemotherapy plus new drugs. The study was presented at the 35th ESMO Congress by Federica Cavallo, MD, second author, from Azienda Ospedaliera Universitaria San Giovanni Battista of Torino, Italy. [Read Article]

Anthracyclines safe in select elderly NHL patients

Alice Goodman Read Article
Published: 10/22/10

DLBCL cells
DLBCL cells

Treatment of elderly patients with non-Hodgkin’s lymphoma (NHL) is becoming increasingly important, particularly since the fastest-growing segment of the population is people over the age of 65 years. A small study presented at the 35th ESMO Congress showed that anthracycline-containing chemotherapy can be safely administered to older NHL patients with good clinical outcomes. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}